Диссертация (1174314), страница 27
Текст из файла (страница 27)
– 2007. –Vol.22. – №3. – P.644-653.120. Birkhauser M., Braendle W., Keller P.J. et al. Recommendations forhormonal contraception. 36th Professional Meeting of the «Zurich Discussion Group»,April 2006 // Gynakol Geburtshifliche Rundsch. – 2007. – Vol.47. – №2. – P.94-98.121. Blumenfeld Z. Ovarian cryopreservation versus ovarian suppression byGnRH analogues: priumum non nocere // Hum Reprod. – 2004. – Vol.19. – №8. –P.1924-1925.160122.
Borqhese B., Barbaux S., Mondon F. et al. Research resourse: genome-wideprofiling of methylated promoters in endometriosis reveals a subtelomeric location ofhypermethylation // Mol Endocrinol. – 2010. – Vol.24. – №.9. – P.1872-1885.123.
Brown J., Pan A., Hart R.J. Gonadotropin-releasing hormone analogues forpain associated with endometriosis // Cochrane Database Syst Rev. – 2010. – Vol.12. –CD008475.124. Brown J., Crawford T.J., Datta S., Prentice A. Oral contraceptives for painassociated with endometriosis // Cochrane Database Syst Rev. – 2018. – Vol.22. – №5. –CD001019.125. Bukulmez 0., Hardy D.B., Carr B.R. et al. Inflammatory status influencesaromatase and steroid receptor expression in endometiosis // Endocrinolgy.
– 2008. –Vol.149. – №.3. – P.1190-1204.126. Bullwinkel J., Baron-Luhr B., Ludemann A., Wohlenderg C., Gerdes J.,Scholzen T. Ki-67 protein is associated with ribosomal RNA transcription in quiescentand proliferation cells // J. Cell. Physiol. – 2006. – Vol.3. – P. 624-635.127. Bulun S.E., Chenq Y.H., Pavone M.E. et al. Estrogen receptor-beta, estrogenreceptor-alpha, and progesterone resistance in endometiosis // Semin Reprod Med.
–2010. – Vol.28. – №.1. – P.36-43.128. Bulun S.E., Lin Z., Imir G. et al. Regulation of aromatase expression inestrogenresponsive breast and uterine disease: from bench to treatment // PharmacolRev. – 2005. – №.57. – P.359-383.129. Bunch K., Tinnemore D., Huff S. et al Expression patterns of progesteronereceptor membrane components 1 and 2 in endometria from women with and withoutendometriosis // Reprod Sci. – 2014. - 21(2). – P.190-197.130. Burney R.O., Giudice L.C. Pathogenesis and pathophysiology ofendometriosis // Fertil Steril.
– 2012. – Vol.98. – №.3. – P.511-519.131. Campani R., Bottinelli O., Calliada F., Coscia D. The latest in ultrasound:three-dimensional iaging. Part II // Eur J Radiol. – 1998. – Vol.27. – №2. – P.183-187.132. Capobianco A., Rovere-Querini P. Endometriosis, a disease of themacrophage // Front Immunol.
– 2013. – Vol.4. – №.9.161133. Carmona F., Chapron C., Martinez-Zamora M.A. et al. Ovarianendometrioma but not deep infiltrating endometriosis is associated with increased serumlevels of interleukin-8 and interleukin-6 // J Reprod Immunol. – 2012. – Vol.95. – №1-2.– P.80-86.134. Carmona F., Martinez-Zamora M.A., Rabanal A. et al. Ovarian cystectomyversus laser vaporization in the treatment of ovarian endometriomas: a randomizedclinical trial with a five-year follw-up // Fertil Steril.
– 2011. – Vol.96. – №1. –P.251-254.135. Carneiro M.M., Morsch D.M., Camarqos A.F. et al. Expression of17beta-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis // GynecolEndocrinol. – 2007. – Vol.23. – №.4. – P.188-192.136. Chandra A., Rho A.M., Jeong K. et al. Clinical experience of long-term useof dienogest after surgery for ovarian endometrioma // Obstet Gynecol Sci. – 2018.
–Vol.61. – №1. – P.111-117.137. Cho S., Choi Y.S., Jeon Y.E. et al. Expression of vascular endothelial growthfactor (VEGF) and its soluble receptor-1 in endometriosis // Microvasc Res. – 2012. –Vol.83. – №2. – P.237-242.138. Cho S., Oh Y., Nam A. et al. Evaluation of serum and urinary angiogenicfactors in patients with endometriosis // Am J Reprod Immunol. – 2007. –№58. –P.497504.139. Cho S., Park S.H., Choi Y.S.
et al. Expression of cyclogenase-2 in eutopicendometium and ovarian endometriotic tissue in women with severe endometriosis //Gynecol Obstet Invest. – 2010. – Vol.69. – №2. – P.93-100.140. Collette T., Maheux R., Mailloux J., Akoum A. Increased expression ofmatrix metalloproteinase-9 in the eutopic endometrial tissue of women withendometriosis // Hum Reprod. – 2006.
– Vol.21. – №12. – P.3059-3067.141. Dai L., Gu L., Di W. MiR-199a attenuates endometrial stromal cellsinvasiveness through suppression of the IKKβ/NF-kB pathway and reducedinterleukin-8 expression // Mol Hum Reprod. – 2012. – Vol.18. – №3. – P.136-145.162142. DanH.,LiminF.Laparoscopicovariancystectomyversusfenestration/coagulation or laser vaporization for the treatment of endometriomas: ameta-analysis of randomized controlled trials // Gnecol Obstet Invest.
– 2013. – Vol.76.– №2. – P.75-82.143. Di Carlo C., Bonifacio M., Tommaselli G.A. et al. Metalloproteinases,vascular endothelial growth factor, and angiopoietin 1 and 2 in eutopic and ectopicendometrium // Fertil Steril. – 2009. – Vol.91. – №6. – P.2315-2323.144. Drapkin R., von Horsten H., Lin Y. et al. Human epididymis protein 4 (HE4)is a secreted glycoprotein that is overexpressed by serous and endometrioid ovariancarcinomas // Cancer Res.
– 2005. – Vol.65. – P.2162-2169.145. Eltabbakh G.H., Bower N.A. Laparoscopic surgery in endometriosis //Minerva Ginecol. – 2008. – Vol.60. – №4. – P.323-330.146. El-Sahwi K., El-Faham M., El-Sahwi S. Laparoscopic management ofovarian endometriomas: incision peeling versus coagulation // Proceedings of XIXWorld Congress on Fertility and Sterility. Durban, South Africa, 2007. – FC1502.
–P.78.147. Fairbanks F., Abrao M.S., Podgaec S. et al. Interleukin-12 but notinterleukin-18 is associated with severe endometriosis // Fertil Steril. – 2009. – Vol.91. –P.320-342.148. Falkone T., Lebovic D.I. Clinical management of endometriosis // ObstetGynecol. – 2011. – Vol.118 – №3. – P.691-705.149. Farrell E., Garad R. Endometiosis // Aust Nurs J. – 2012. – Vol.20. – №5. –P.37-39.150. Ferrero S., Venturini P.L., Gillott D.J.
et al. Hemostatis by bipolarcoagulation versus suture after surgical stripping of bilateral ovarian endometriomas: arandomized controlled trial // J Minim Invasive Gynecol. – 2012. – Vol.19. – №6. –P.722-730.151. Ferrero, S., Scala C., Racca A. et al. Second surgery for recurrent unilateralendometriomas and impact on ovarian reserve: a case-control study // Fertil Steril. –2015. - №103(5). – Р.1236-43.163152. Fuldeore M.J., Soliman A. M. Prevalence and Symptomatic Burden ofDiagnosed Endometriosis in the United States: National Estimates from a CrossSectional Survey of 59,411 Women // Gynecol Obstet Invest.
– 2017. – Vol.82. – №5. –P.453-461.153. Galgano M., Hampton G., Frierson H.J. Comprehensive analysis of HE4expression in normal and malignant human tissues // Mod Pathol. – 2006. – Vol.19. –P.847-853.154. Gilabert-Estelles J., Ramon L.A., Espana F. et al. Expression of angiogenicfactors in endometriosis: relationship to fibrinolytic and metalloproteinase systems //Hum Reprod.
– 2007. – Vol.22. – №8. – P.2120-2127.155. Giudice L.C. Clinical practice. Endometriosis // N Engl J Med. – 2010. –Vol.362. – №.25. – P.2389-2398.156. Graham J.D., Hanson A.R., Croft A.J. et al. Nuclear matrix binding is criticalfor progesterone receptor movement into nuclear foci // Faseb J. – 2009. – Vol.23. –P.546-556.157. Guerriero S., Van Calster B., Somigliana E., Ajossa S. Age-relateddifferences in the sonographic characteristics of endometriomas // Hum Reprod. - 2016.- №31 (8). – Р.1723-1731.158. Guo S.W. Enetging drugs for endometriosis // Expert Opin Emerg Druqs. –2008. – Vol.13.
– №.4. – P.547-571.159. Guo SW. Recurrence of endometriosis and its control // Hum ReprodUpdate. – 2009. – Vol.15. – P.441–461.160. Halme J., Becker S., Haskill S. Altered maturation and function of peritonealmacrophages: possible role in pathogenesis of endometriosis // Am J Obstet Gynecol. –1987. – №.156. – P.783.161. Halme J., Hamond M.G., Hulka J.F. et al. Retrograde menstruation in helhywomen and in patients with endometriosis // Obstet Gynecol.
– 1984. – Vol.64. – №.2. –P.151-154.162. Han A.R., Lee T.H., Kim S., Lee H.Y. Risk factors and biomarkers for therecurrence of ovarian endometrioma: about the immunoreactivity of progesterone164receptor isoform B and nuclear factor kappa B // Gynecol Endocrinol. – 2017. - №33(1). – Р.70-74.163. Han Y.J., Kim H.N., Yoon J.K. et al. Hapltype analysis of the matrixmetalloproteinase-9 gene associated with advacdes-stage endometriosis // Fertil Steril.
–2009. – Vol.91. – №6. – P.2324-2330.164. Harada T., Momoeda M., Taketani Y. et al. Dienogest is as effective asintranasal buserelin acetate for the relif of the pain symptoms associated withendometriosis – a randomized, double-blind, multicenter, controlled trial // Fertil Steril.– 2009. – Vol.91. – №3. – P.675-681.165. Harris H.A. The unexpressed science of estrogen receptor-β selectiveagonists: a new class of anti-inflammatory agents? // Nucl Recept Signal. – 2006. – №4.– e012.166. Havrilesky L., Whitehead C., Rubatt J.
et al. Evaluation of biomarker panelsfor early stage ovarian cancer detection and monitoring for disease recurrence //Gynecol, Oncol. – 2008. – Vol.110. – P.374-382.167. Hayashi A., Tanabe A., Kawabe S. et al. Dienogest increases theprogesrerone receptor isoform B/A ratio in patients with ovarian endometriosis // JOvarian Res. – 2012. – №5. – P.31-38.168. Hellstrom I., Hellstrom K.
SMRP and HE4 as biomarkers for ovariancarcinoma when used alone and in combination with CA125 and/or each other // AdvExp Med Biol. – 2008. – Vol.622. – P.15-21.169. Horie S., Harada T., Mitsunari M. et al. Progesterone and progestationalcompounds attenuate tumor necrosis factor alpha-induced interleukin-8 production vianuclear factor kappa B inactivation in endometriotic stromal cells // Fertil Steril. – 2005.– №.83. – P.1530-1535.170. Hua Z., Lv Q., Ye W.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
